Alnylam Pharmaceuticals
ALNY
#622
Rank
A$50.63 B
Marketcap
$392.56
Share price
2.75%
Change (1 day)
47.30%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Net assets

Net assets on the balance sheet as of September 2024 : A$51.74 Million

According to Alnylam Pharmaceuticals 's latest financial reports the company has A$51.74 Million in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

Alnylam Pharmaceuticals - Net assets on balance sheet (from 2003 to 2024)

Net assets by year

Year Net assets Change
2023-12-31$-A$0.33 Billion39.29%
2022-12-31$-A$0.24 Billion-128.66%
2021-12-31$A$0.81 B-38.61%
2020-12-31$A$1.32 B-35.68%
2019-12-31$A$2.05 B11.19%
2018-12-31$A$1.84 B-18.32%
2017-12-31$A$2.26 B77.23%
2016-12-31$A$1.27 B-26.46%
2015-12-31$A$1.73 B51.75%
2014-12-31$A$1.14 B277.46%
2013-12-31$A$0.30 B134.96%
2012-12-31$A$0.12 B12.09%
2011-12-31$A$0.11 B-26.12%
2010-12-31$A$0.15 B-21.37%
2009-12-31$A$0.19 B-30.85%
2008-12-31$A$0.28 B25.76%
2007-12-31$A$0.22 B-10.73%
2006-12-31$A$0.25 B202.25%
2005-12-31$A$84.43 M41.6%
2004-12-31$A$59.62 M-265.95%
2003-12-31$-A$35.94 Million335.71%
2002-12-31$-A$8.25 Million

Net assets for similar companies or competitors

Company Net assets differencediff. Country
A$0.30 B 490.54%๐Ÿ‡บ๐Ÿ‡ธ USA
A$46.90 B 90,540.72%๐Ÿ‡บ๐Ÿ‡ธ USA
A$1.95 B 3,674.09%๐Ÿ‡บ๐Ÿ‡ธ USA
A$2.24 B 4,237.70%๐Ÿ‡บ๐Ÿ‡ธ USA
A$0.13 B 168.30%๐Ÿ‡บ๐Ÿ‡ธ USA
A$69.47 B 134,167.79%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
A$125.15 B 241,760.67%๐Ÿ‡ซ๐Ÿ‡ท France
A$10.21 B 19,631.72%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel